Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-napht hyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
US5250435A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 4, 1991 |
| Grant date | Oct 5, 1993 |
| Priority date | — |
| Expiry date | Jun 4, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/913
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Novel strains of Aspergillus terreus have been discovered which provide fermentation production of at least 5.2 g/L of 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl ]-3(R),5(R)-dihydroxyheptanoic acid (triol acid, I), but with production of not more than 0.85 g/L of (triol acid)-related side products and specifically less than 0.10 mg/liter of lovastatin. The predominant fermentation product triol acid, may be converted in a straightforward manner to its lactone form, in which it is an inhibitor of HMG-CoA reductase and thus useful as an antihypercholesterolemic agent, and in which it may also serve as an intermediate for preparation of other HMG-CoA reductase inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.